ES2109495T3 - Tioureas sustituidas utilizadas como agentes quelantes bifuncionales. - Google Patents

Tioureas sustituidas utilizadas como agentes quelantes bifuncionales.

Info

Publication number
ES2109495T3
ES2109495T3 ES93911594T ES93911594T ES2109495T3 ES 2109495 T3 ES2109495 T3 ES 2109495T3 ES 93911594 T ES93911594 T ES 93911594T ES 93911594 T ES93911594 T ES 93911594T ES 2109495 T3 ES2109495 T3 ES 2109495T3
Authority
ES
Spain
Prior art keywords
pct
chelating agents
bifunctional chelating
substituted thioureas
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93911594T
Other languages
English (en)
Inventor
Daniel J Coughlin
Benjamin A Belinka Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp filed Critical Cytogen Corp
Application granted granted Critical
Publication of ES2109495T3 publication Critical patent/ES2109495T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

LA INVENCION ES RELATIVA A AGENTES DE QUELACION DE FORMULA (I), EN QUE L ES UN ENLAZADOR; D ES UN SOPORTE PARA ALQUILO, SOPORTE PARA ALQUILO CICLICO O GRUPO DE SOPORTE PARA ARILO SUSTITUIDO CON LOS GRUPOS NHCSNHR; Y R ES HIDROGENO O UN SUSTITUYENTE DE FORMULA GENERAL (I) EN LA QUE A = 0 O 1; B = 0-10; C = 0 O 1; SI C = 1, Y = S, O H2; D = 0-2; E = 0-10; Y Z = H, N+(R'')3X-, SO3H, CO2H, OH, H2PO3; EN QUE X OMO UN HALURO O UN ANION ACIDO Y R'' ES UN ALQUILO INFERIOR C1 AC4, USADO PARA ACOPLAR IONES METALICOS A MOLECULAS BIOLOGICAMENTE ACTIVAS. EN PARTICULAR, TIOUREAS SUSTANCIALES PARA QUELAR METALES TALES COMO TECNETIO ESTA PROVISTO QUE PUEDAN SER CONJUGADAS A MOLECULAS DE DESTINO TALES COMO UN ANTICUERPO, UN PEPTIDO O UNA PROTEINA.
ES93911594T 1992-04-09 1993-04-08 Tioureas sustituidas utilizadas como agentes quelantes bifuncionales. Expired - Lifetime ES2109495T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/866,375 US5326856A (en) 1992-04-09 1992-04-09 Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding

Publications (1)

Publication Number Publication Date
ES2109495T3 true ES2109495T3 (es) 1998-01-16

Family

ID=25347475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93911594T Expired - Lifetime ES2109495T3 (es) 1992-04-09 1993-04-08 Tioureas sustituidas utilizadas como agentes quelantes bifuncionales.

Country Status (8)

Country Link
US (3) US5326856A (es)
EP (1) EP0635001B1 (es)
JP (1) JPH08502240A (es)
AT (1) ATE157084T1 (es)
CA (1) CA2117770A1 (es)
DE (1) DE69313272T2 (es)
ES (1) ES2109495T3 (es)
WO (1) WO1993021151A1 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567411A (en) * 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US7238340B1 (en) 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5508020A (en) 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
PT676965E (pt) * 1992-11-16 2007-10-29 Centocor Inc Método para reduzir a imunogenicidade da região variável de anticorpos
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US5951964A (en) * 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
GB2284208A (en) * 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5863536A (en) * 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US6025344A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6025345A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
RU2218179C2 (ru) 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
CZ60499A3 (cs) 1996-09-27 1999-08-11 Guilford Pharmaceuticals Inc. Prostředky s účinkem na NAALADázy, způsoby léčení glutamátové abnormality a způsoby ovlivňování neuronální aktivity u živočichů
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
DE69927502T2 (de) 1998-07-06 2006-07-06 Mgi Gp, Inc. (N.D.Ges.D. Staates Delaware) Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
CA2383086A1 (en) * 1999-09-08 2001-03-15 Joseph P. Steiner Non-peptidic cyclophilin binding compounds and their use
US20020077435A1 (en) * 2000-10-09 2002-06-20 Desimone Joseph M. Methods for preparing polymers in carbon dioxide having reactive functionality
CN100352805C (zh) 2000-11-08 2007-12-05 鲁汶天主教大学研究开发部 用作造影剂的取代的联吲哚衍生物、包含它们的药物组合物以及制造它们的中间体
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
EP2360476B1 (en) 2002-02-13 2017-10-25 BioMedica Diagnostics Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
WO2005117997A1 (en) * 2004-06-01 2005-12-15 The Ohio State University Ligands having metal binding ability and targeting properties
JP2008515875A (ja) * 2004-10-07 2008-05-15 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 医療のイメージングに用いる化合物、キット及び方法
WO2006069203A2 (en) 2004-12-22 2006-06-29 California Institute Of Technology Methods for proteomic profiling using non-natural amino acids
WO2007039864A2 (en) * 2005-10-04 2007-04-12 Koninklijke Philips Electronics N.V. The staudinger reaction in imaging and therapy and kits for use in imaging and therapy
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
BRPI0709138A2 (pt) * 2006-03-28 2011-06-28 Konink Philips Eletronics N V combinação de dois ou mais componentes de um composto biologicamente ativo intacto, composição farmacuêtica, primeiro componente de um composto biologicamente ativo intacto, e, métodos para preparar componentes de bleomicina e para aumentar a absorção de um composto biologicamente ativo intacto
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
BRPI0814763A2 (pt) * 2007-08-09 2015-03-03 Syntonix Pharmaceuticals Inc Peptídeos imunomoduladores
GB0807237D0 (en) * 2008-04-21 2008-05-28 Crown Packaging Technology Inc Cutting method and apparatus
ES2624637T3 (es) * 2008-05-30 2017-07-17 Atotech Deutschland Gmbh Aditivo de electrogalvanoplastia para la deposición de una aleación de un metal del grupo IB/binaria o ternaria del grupo IB-grupo IIIA/ternaria, cuaternaria o quinaria del grupo IB, el grupo IIIA-grupo VIA
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2627358B1 (en) 2010-10-14 2024-03-27 Tagworks Pharmaceuticals B.V. Pretargeting kit, method and agents used therein
RU2013133813A (ru) 2010-12-21 2015-01-27 Конинклейке Филипс Электроникс Н.В. Средства для выведения биомолекул из кровотока
EP2522369A1 (en) 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
EP2707394A4 (en) 2011-05-12 2015-06-24 Metallopharm Llc METALLO-MEDICINES HAVING IMPROVED PHARMACOLOGICAL PROPERTIES, AND METHODS OF MAKING AND USING THEM
US8933016B2 (en) 2012-01-18 2015-01-13 MetalloPharm, LLC Metallodrugs having improved pharmacological properties and methods of manufacture and use thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN102702056B (zh) * 2012-05-31 2014-09-24 北京师范大学 一种一锅法合成取代间苯二异硫氰酸酯的方法、合成的取代间苯二异硫氰酸酯化合物
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
EA035324B1 (ru) 2013-12-24 2020-05-28 Ардженкс Бвба АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FCRN) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
JP6899321B2 (ja) 2014-09-08 2021-07-07 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 糖脂質を使用するヒトｉＮＫＴ細胞活性化
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
DK3268391T3 (da) 2015-03-09 2021-09-13 Argenx Bvba Fremgangsmåder til reduktion af serumniveauer af Fc-indeholdende midler ved anvendelse af FcRn-antagonister
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11591388B2 (en) 2019-06-07 2023-02-28 argenx BV Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
AU2020297253B2 (en) 2019-06-17 2024-05-23 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307250A (en) * 1970-06-16 1973-02-14 May & Baker Ltd Benzene derivatives
US4048326A (en) * 1970-06-16 1977-09-13 May & Baker Limited Treatment of helminth infections with substituted 1,2-bis(thioureido)benzene
US4072696A (en) * 1973-02-12 1978-02-07 Syntex (U.S.A.) Inc. 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
US4086235A (en) * 1976-04-12 1978-04-25 Syntex (U.S.A.) Inc. 5 (6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
US4060636A (en) * 1976-06-10 1977-11-29 Rohm And Haas Company Acetyl- and carbalkoxythioureidobenzophenones as anthelmintic agents
DE3060377D1 (en) * 1979-08-29 1982-07-01 Nihon Mediphysics Co Ltd 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4980147A (en) * 1984-06-25 1990-12-25 University Of Utah Research Foundation Radiolabeled technetium chelates for use in renal function determinations
ATE66469T1 (de) * 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
WO1987004164A1 (en) * 1986-01-06 1987-07-16 The University Of Melbourne Technetium-antibody conjugate
US4732974A (en) * 1986-03-05 1988-03-22 Mallinckrodt, Inc. Metal ion labeling of carrier molecules
EP0247571B1 (de) * 1986-05-28 1991-08-28 LTS Lohmann Therapie-Systeme GmbH & Co. KG Fixiersystem zur Befestigung von Kathetern, Kanülen oder dgl. auf der Hautoberfläche
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
EP0354923B1 (en) * 1987-04-02 1994-06-29 Centocor, Inc. Method for labelling antibodies with a metal ion
IL87405A0 (en) * 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
US5101041A (en) * 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
US5080884A (en) * 1989-12-12 1992-01-14 Medi-Physics, Inc. Hydrocarbylphenyl diaminodithiol radionuclide complexes and their use in imaging
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding

Also Published As

Publication number Publication date
WO1993021151A1 (en) 1993-10-28
ATE157084T1 (de) 1997-09-15
DE69313272T2 (de) 1998-04-02
EP0635001B1 (en) 1997-08-20
US5326856A (en) 1994-07-05
CA2117770A1 (en) 1993-10-28
EP0635001A1 (en) 1995-01-25
JPH08502240A (ja) 1996-03-12
US5585468A (en) 1996-12-17
US5527885A (en) 1996-06-18
DE69313272D1 (de) 1997-09-25

Similar Documents

Publication Publication Date Title
ES2109495T3 (es) Tioureas sustituidas utilizadas como agentes quelantes bifuncionales.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DE69326335D1 (de) Technetium-99M-markierte peptide zur Bilderzeugung
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
ATE58297T1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
DE59508391D1 (de) Metallkomplexe mit geladenem linker
ES2143059T3 (es) Complejos metalicos hidrofilos.
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ES2051806T3 (es) Preparados de proteina humana estables.
AU8188987A (en) Improved metal complex-containing pharmaceutical agents
ATE296312T1 (de) Metalkomplexbildner
DE69837613D1 (de) J-kette und analoge für konjugate zielgerichtet auf epithelzellen
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
UA65561A (en) Therapeutic agent for lymphatic tumors
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
GR3024667T3 (en) Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use.
NZ504291A (en) Compositions and methods for targeted delivery of factors
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR199701335T1 (xx) Diatomlu toprak ha�erat bile�imi
NO970141L (no) Konjugater av metallkomplekser og oligonukleotider, midler inneholdende konjugatene, deres anvendelse ved radiodiagnose samt fremgangsmåte for deres fremstilling
DE60006587D1 (de) Makrozyclische liganden für metallpharmazeutika
WO1998051792A8 (en) Fac molecules and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 635001

Country of ref document: ES